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Nesfatin-1, a newly discovered NUCB2-derived satiety neuropeptide is expressed in 
several neurons of forebrain, hindbrain, brainstem and spinal cord. This novel 
anorexigenic substance seems to play an important role in hypothalamic pathways 
regulating food intake and energy homeostasis.  Nesfatin-1 immunoreactive cells are 
detectable in arcuate (ARC), paraventricular (PVN) and supraoptic nuclei (SON), 
where the peptide is colocalized with POMC/CART, NPY, oxytocin and vasopressin. 
The nesfatin-1 molecule interacts with a G-protein coupled receptor and its 
cytophysiological effect depends on inhibitory hyperpolarization of NPY/AgRP 
neurons in ARC and melanocortin signaling in PVN.  Administration of nesfatin-1 
significantly inhibits consumatory behaviour and decreases weight gain in 
experimental animals. These recent findings suggest the evidence for nesfatin-1 
involvement in other important brain functions such as reproduction, sleep, 
cognition and anxiety- or stress-related responses. The neuroprotective and 
antiapoptotic properties of nesfatin-1 were also reported. From the clinical viewpoint 
it should be noteworthy, that the serum concentration of nesfatin-1 may be a 
sensitive marker of epileptic seizures. However, the details of nesfatin-1 physiology 
ought to be clarified, and it may be considered suitable in the future, as a potential 
drug in the pharmacotherapy of obesity, especially in patients treated with 
antipsychotics and antidepressants. On the other hand, some putative nesfatin-1 
antagonists may improve eating disorders.  
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In recent years, thanks to a dynamic development of molecular biology, a number of 
new regulatory neuropeptides have been identified and described. A great majority of 
them have unique characteristics, a wide multidirectional spectrum of physiological 
activity and act at the level of many neuronal pathways. In this context, a recently 
discovered and still relatively unknown nesfatin-1 (NEFA/NUCB2-encoded satiety and 
fat-influencing protein) appears to be a particularly interesting substance. The first 
information regarding its existence was provided in 2006 by Oh et al., as result of 
studies on lung carcinoma cell lines, revealing the expression of leptin receptors 
following activation by the PPAR- ligand - troglitazone. Presently, research studies on 
nesfatin-1 and its neurophysiological properties are still in their initial phase. 
Nesfatin-1 is a potent anorexigenic factor inducing satiety and strongly inhibiting food 
and water intake (Stengel and Tache 2010, Stengel et al. 2010a, Pałasz et al. 2010, 
Shimizu et al. 2009). Upon direct injection to a lateral ventricle of the rat brain, it causes 
a dose dependent depression of consumatory behaviour. Continuous infusion to the III-
rd ventricle results in a significant reduction of body mass and in a decreased amount of 
white adipose tissue. An intraperitoneal injection of nesfatin-1 induces a 3- hour 
suppression of food intake in mice. Also, its subcutaneous administration induces the 
identical effect, and this anorexigenic action can be maintained for 14 hours. Repeated 
intraperitoneal doses have substantially inhibited the increase of body mass, over a 6-
day period (Shimizu et al. 2009). It should be underlined that the peripheral nesfatin-1 doses 
required to suppress food intake are approximately 1000-fold higher than those effective in the 
CNS (Stengel et al. 2010a). 
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Serum levels of nesfatin-1 are substantially decreased in the state of starvation, while 
refeeding leads to normalization. Nesfatin-1 penetrates the blood-brain barrier (Pan et 
al. 2007) that may potentially create an opportunity for its putative therapeutic use. It 
appears that after reaching the hypothalamic centres, nesfatin-1 may inhibit appetite 
and food intake. It has recently been noted that in humans, the CSF/plasma nesfatin-1 
ratio is negatively correlated with body mass index (BMI) and body mass, possibly 
suggesting that nesfatin-1 is a protein-bound neuropeptide. A hypothesis has been 
proposed that, dependent on body mass changes, efficiency of nesfatin-1 uptake by the 
CSF can be caused by saturation of its transporters (Tan et al. 2011). Recently, studies 
clearly suggesting the participation of nesfatin-1  in brain actions diverse from energy 
balance regulation have been published. Nesfatin-1 appears to be a neuropeptide that 
plays a significant role in reproductive processes, stress responses, and pathology of 
mental and neurological disorders (Könczöl et al. 2010, Ogiso et al. 2011, Aydin et al. 
2011, Stengel and Tache 2011). These completely innovative aspects of nesfatin-1 
physiology are more extensively presented in subsections of this review. 
With regard to the anorectic properties of nesfatin-1, the recent presumption that it can 
display some characteristics of neuroprotective factors seems particularly intriguing. At 
the present time, the only source of these suggestions is the study conducted by Özsavci 
et al., in 2010, who examined the influence of nesfatin-1, administered 
intraperitoneally, on the profile of oxidative stress markers and the permeability of 
blood-brain barrier in rats with subarachnoid hemorrhage (SAH). The authors have 
noted that the levels of SAH-induced oxidative brain injury markers and plasma levels of 
pro-inflammatory cytokines: TNF-, IL-1, and IL-6 as well as proapoptotic protein 
caspase-3 were significantly decreased in animals exposed to the actions of nesfatin-1. 
Moreover, these authors have reported that nesfatin- 1 reduced the, SAH-dependent, 
histological structural changes of basilar arteries by inhibiting neutrophil infiltration. 
This research allows us to deduce that nesfatin-1 can play the role of anti-inflammatory 
and antiapoptotic factor in the central nervous system. However, as of today, it is still 
too early to conclude that nesfatin-1 represents a compound which plays the key role in 
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the neuroprotective mechanisms of the brain. There is no doubt that this remarkably 
interesting issue requires further experimental studies.  
 
1.2 Molecular structure  
Formation of the 82-amino acid molecule nesfatin-1 is the effect of posttranslational 
cleavage of prohormone NEFA/nucleobindin-2 (NUCB2), performed by the specific 
convertases PC3/1 and PC2 (Garcia-Galiano et al. 2010, Stengel and Tache 2010). 
NUCB2, a polypeptide composed of 396 amino acids (aa), preceded by a 24-aa signal 
peptide is located both on the plasma membrane and in the neuroplasm. This precursor 
protein consists of the following domains: N-terminal signal peptide, Leu/Ile rich region, 
DNA-binding domain, nuclear targeting signal, two Ca2+-EF-hand motifs and leucine 
zipper domain (Stengel et al 2010a). Nesfatin-1 has a substantial, above 85% homology, 
of its sequences between humans and mammals, and even the lower vertebrates 
(Gonzales et al. 2010). The nesfatin-1 molecule is composed of 3 domains: N-terminal 
(N23), middle part (M30) and C-terminal (C29). The M30 active core appears to play the 
key role in the induction of physiological effects of this peptide, and especially in its 
anorectic responses (Fig1. A). Another effect of the NUCB2 proteolytic processing is a 
production of its inactive derivatives: nesfatin 2 and 3, spanning residues 85-163 and 









In the rat hypothalamus, neurons localized in the arcuate nucleus (ARC), paraventricular 
nucleus (PVN), supraoptic nucleus (SON), dorsomedial (DMH), lateral hypothalamus 
(LHA), and zona incerta are characterized by expression of nesfatin-1 (Stengel et al. 
2010a, Shimizu et al. 2009). It is assumed that the anorexigenic action of nesfatin-1 is 
performed mostly in the first three key regulatory hypothalamic centres. The nesfatin-1 
immunopositive neurons are also present in the brain stem, including serotoninergic 
cells – of the raphe pallidus (RPa), raphe obscurus (ROb), and cholinergic cells – of the 
nucleus accessorius of oculomotor nerve (nucleus Westphal-Edinger; EW), and nucleus 
dorsalis of vagus nerve (Foo et al. 2008). Since some sympathetic axons originate from 
the raphe nuclei and terminate in brown adipose cells, it is suggested that nesfatin-1 
takes part in the regulation of thermogenesis (Brailoiu et al. 2007). It is also possible 
that nesfatin-1, which is released from the synaptic endndings’ of the vagus nerve, can 
have an impact on secretory and motor activity of the gastrointestinal tract, and may 
regulate the course of digestive functions (Stengel et al. 2010a, Goebel et al. 2009). On 
the other hand, it has recently been demonstrated that pretreatment with capsaicin (to 
block autonomic C fibres) abolished the food intake reduction caused by peripheral 
nesfatin-1 injection. These findings indicate a putative role of vagal afferents in 
peripheral nesfatin-1 signaling to the brain centres (Shimizu et al. 2009). As further 
evidence to this, it has been demonstrated that nesfatin-1 activates cell bodies in the 
nodose ganglion in vitro. This assembly of neurons contains the perikarya of vagal nerve 
fibres projecting to the nucleus of the solitary tract (Iwasaki et al. 2009). The nesfatin-1 
contribution to the physiological functions of the oculomotor nerve has not been clearly 
explained (Goebel et al. 2009). In addition, perikarya of the piriform, insular and 
cingulate cortex, endopiriform nucleus, lateral septum, anterior cortical and central 
amygdaloid nucleus, bed nucleus of stria terminalis and interstitial nucleus of the 
posterior limb of anterior commissure, are also characterized by nesfatin-1 
immunoreactivity.  The neuropeptide was also identified in other structures of brain 
stem, in nucleus of the solitary tract (NST),in dorsal raphe nucleus, raphe magnus 
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nucleus, gigantocellular reticular nucleus, lateral parabrachial nucleus, nucleus 
ambiguous, central gray (nucleus O), and even in the Purkyne’s cells of cerebellar cortex. 
Moreover, the presence of nesfatin-1 was detected in sympathetic and parasympathetic 
preganglionic neurons, originating from thoracic, lumbar and sacral segments of the 
spinal cord (Goebel et al. 2009). One of the achievements of new experimental research 
was the discovery of nesfatin-1 in those regions of animal brain in which it was not 
previously identified. Although the distribution of nesfatin-1 in the mice brain is in 
general very similar to the one observed in rat, many other previously unknown areas in 
which this peptide is encountered including: anterior olfactory nucleus (AOL), 
accumbens nucleus (Ac), caudate putamen, piramidal cell layer of the hippocampus, 
dorsal and dorsolateral tegmental nuclei, nucleus of the facial nerve, area postrema, 
inferior olivary nucleus, and a newly identified region, called intermediate  dorsomedial 
hypothalamus (IDMH) were found in these species (Goebel-Stengel et al. 2011). 
Distribution of nesfatin-1 in perikarya of autonomic brain centres, preganglionic visceral 
motoneurons of spinal cord, and forebrain nuclei involved in pain perception and in 
cognitive processes, seems to confirm a presumption that the physiological role of this 
neuropeptide is far beyond the sphere of food-intake regulation. In particular, it 
participates in vasomotor, neurosecretory, and emotional functions. 
Although, the present article emphasizes the nesfatin-1 activity in some brain 
structures, the fact that the expression of this peptide has also been revealed in cells of 
some other organs cannot be neglected. In particular, nesfatin-1 has been identified in 
gastric glands, in submucosal layer of the duodenum (Zhang et al. 2010), and in B cells of 
the pancreatic islets (Foo et al. 2010). It should be mentioned, that in the gastric glands, 
the majority of nesfatin-1 immunopositive X/A-like endocrine cells are characterized by 
coexpression of ghrelin, an orexigenic hormone (Stengel et al. 2010), and only a small 
number of these cells reveals the presence of somatostatin (Maejima et al. 2009, 
Stengel et al. 2009). The newest reports suggest that in vitro, nesfatin-1 augments the 
glucose-induced insulin secretion through the activation of L-type calcium channels in 
the B cells of mice (Nakata et al. 2011 Gonzalez et al. 2011). In turn, an elevated glucose 
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level increases significantly the nesfatin-1 release by pancreatic endocrine cells (Foo et 
al. 2010). It has been reported that the administration of nesfatin-1 reduces a blood 
glucose level in mice with a hyperglycemic genetic profile (Su et al. 2010). Expression of 
NUCB2 and nesfatin-1 has also been revealed in human and murine adipocytes. It is 
noteworthy that this expression is particularly evident in the subcutaneous fat tissue 
cells (Ramajaneya et al. 2010). Recently, some preliminary reports regarding 
identification of the nesfatin-1 immunopositive cells in testis and ovaries of rat have 
appeared in the literature. (Garcia-Galiano et al. 2010a). 
 
2. Anorexigenic activity of nesfatin-1 at the level of hypothalamus 
 
2.1. Mode of action in the arcuate nucleus 
The arcuate nucleus (ARC), which is excluded from the blood-brain barrier, is one of the 
hypothalamic structures participating in energy balance regulation. It’s neurons are 
characterized by a particular sensitivity to peripheral hormonal signals such as 
circulating blood molecules of adipokines, ghrelin, insulin, cholecystokinin (CCK), 
peptide YY (PYY), oxyntomodulin, and some other compounds. A structure of ARC 
consists of two functionally antagonistic groups of neurons. The first group is composed 
of cells, which synthesize orexigenic factors - neuropeptide Y (NPY) and Agouti-related 
protein (AgRP). The second group contains neurons producing pro-opiomelanocortin 
(POMC), which has active derivatives, including a-MSH and cocaine-amphetamine 
regulated transcript (CART), characterized by anorexigenic properties. It was originally 
suggested that only the POMC/CART neurons of the rat hypothalamus are characterized 
by nesfatin-1 expression, and that in the NPY/AgRP cells this peptide has not been 
identified. However, some later studies have found that the relatively limited population 
of NPY cells (approximately 20%) reveals immunoreactivity of nesfatin-1 that to some 
degree complicates an explanation of the some signaling events in ARC, related to this 
 10 
peptide (Inhoff et al. 2010). A more detailed analysis of coexpression of the nesfatin ARC 
(Fig 2.) profile has revealed that above 60% of ARC cells synthesize POMC and CART, 
46% - NPY, 29% - growth hormone-releasing hormone (GHRH), and 14% - neurotensin 
(Stengel et al. 2010a). Nesfatin-1, which is released from the POMC/CART neurons, 
directly inhibits the NPY/AgRP neurons, causing their hyperpolarization, through the 
ATP-dependent potassium channels Kir6.2. This signaling mechanism can be confirmed by 
an observation that glibenclamide, an antagonist of the same type of K+ channels, 
relieves this peptide’s physiological effect. There are some suggestions that the 
hyperpolarization of orexigenic ARC neurons can be a key phenomenon in anorexia, 
induced by nesfatin-1 (Price et al. 2008). However, according to other reports, nesfatin-
1 contributes to an increase of Ca2+ ion concentration in neuroplasma of the target cells. 
This can be reversed by using pertussis toxin, clearly suggesting that this neuropeptide is 
also a ligand of the metabotropic receptor, connected with G i/o. protein (Fig 1. B). It has 
been found that the receptors activation leads to opening of the L and P/Q-type calcium 
channels, since the use of selective inhibitors of these channels such as verapamil and 
-conotoxin results in removal of the nesfatin-1 dependent influx of Ca2+ ions (Brailoiu 
et al. 2007).   
Interestingly enough, the nesfatin-1 induced elevation of Ca2+ ion concentration is also 
reduced by KT5720, the specific inhibitor of protein kinase A, suggesting a contribution 
of this cAMP – dependent enzyme in the signal transduction process. This is a very 
unusual phenomenon, since the effect of Gi protein activation is ex definition the 
inhibition of adenyl cyclase, causing a decrease of the cAMP concentration, and in 
consequence, inhibition of protein kinase A. One possible explanation of this surprising 
issue is the suggestion that nesfatin-1 is able to activate some different signaling 
pathways, influencing cross-binding of the receptor with various types of G protein, 
initially by activating Gi , and then, by stimulating Gs (Brailoiu et al. 2007). Unfortunately, 
the nesfatin-1 receptor has not been cloned yet. This makes conducting of the detailed 
pharmacological studies impossible. It also  causes some serious difficulties in searching 
for molecules which can be potential modulators. It should be underlined that nesfatin-
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1 is not released from presynaptic axons, but it is secreted by dendrites, and acts as a 
local paracrine or/and autocrine factor (Yosten and Samson 2010). Nesfatin-1 may also 
be involved in deacylation of ghrelin, administered peripherally, which relieves ghrelin’s 
orexigenic action among rats. These actions have been revealed in experimental rat 
studies, in which the nesfatin-1 neurons of the arcuate nucleus were activated through 
simultaneous administration of ghrelin and deacylated ghrelin. Probably, the deacylated 
ghrelin can inhibit the ghrelin sensitive NPY/AgRP neurons by acting through the 
nesfatin-1 releasing cells (Inhoff et al. 2008). It is worth noticing that presently, there is 
no experimental evidence suggesting any contribution of leptin to the nesfatin-1 
anorexigenic mechanisms of action. The blockage of nesfatin-1-dependent signaling 
does not diminish leptin’s physiological effects. In turn, leptin by itself does not appear 
to be a modulator of the NUCB2 and nesfatin-1 expression in hypothalamic nuclei (Oh et 
al. 2006, Garcia-Galiano et al. 2010). It has been known that the feeding suppression by 
leptin occurs via the POMC and CART neurons’ activation, but it has not been reported 
that the nesfatin-1 is capable of stimulation of this group of cells. This observation may 
confirm that nesfatin-1 has its own mode of action, which is leptin-independent 
(Shimizu et al. 2009). Nevertheless, there is some basis to consider that the anorexigenic 
action of nesfatin-1 was made possible through its influence on the hypothalamic 
melanocortin system. The key elements of this signaling pathway are the POMC 
neurons, which are a source of -MSH, as well as PVN and SON cells, rich in MC3 and 
MC4 receptors (discussed in another subsection) (Oh et al. 2006, Yosten and Samson 
2010). 
A great majority (above 75%) of nesfatin neurons located in the tuberal part of the 
hypothalamus reveals coexpression with melanin concentrating hormone (MCH). 
Therefore, one may suppose that nesfatin-1 can be involved in a number of other MCH-
dependent hypothalamic functions such as regulation of autonomic processes, stress 
response, mood, cognitive functions and sleep (Fort et al. 2008).  
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2.2 Interactions with oxytocin, CRF and melanocortin pathway 
 
Expression of nesfatin-1 is also manifested by numerous oxytocinergic and 
vasopressinergic perikarya of the paraventricular nucleus (PVN) and supraoptic nucleus 
(SON). Concentration of nesfatin-1 and the level of expression of NUCB2 in these nuclei 
decreases after 24 days of starvation. Refeeding results in a repeated activation of those 
cells, and is expressed by elevation of c-Fos levels (Kohno et al. 2008). Relatively large 
(on average 43%) group of nesfatin PVN neurons reveals oxytocin expression, but above 
40% of oxytocinergic neurons synthesize nesfatin-1 (Stengel et al. 2010a). This 
cytophysiological correlation allows us to suspect that there are some subtle functional 
associations between these two active hypothalamic peptides. This is confirmed by an 
observation that the action of ornithine vasotocin (OVT), an antagonist of the 
oxytocinergic receptor, relieves the anorexigenic effects of nesfatin-1 in rats.  Nesfatin—
1 is a factor that significantly stimulates oxytocin secretion by magno- and parvocellular 
neurons (PVN) in rat. However, it has not been found that it causes the elevation of 
oxytocin concentration in serum (Yosten and Samson 2010). On the other hand, an 
increase of c-Fos expression in parvocellular neurons (PVN) has been noted.   
There are some reports that the axons of parvocellular oxytocinergic neurons (PVN) 
arrive to the nucleus of solitary tract (NST), an integration area of central and peripheral 
pathways of food intake control, where they exert their inhibitory effect (Blevins et al. 
2004, Sabatier 2006).  Above 50% of PVN nesfatin cells synthesizes vasopressin, and 
about 23% of them  thyreotropin releasing hormone (TRH). Functions of this cell 
population as yet have not been explained(Stengel et al. 2010a). A small (on average 
19%) subpopulation of nesfatin PVN neurons display coexpression of CRF, a factor, 
which inhibits food intake in stressful circumstances, and thus, is suspected to play an 
important role in the pathogenesis of eating disorders (Stengel et al., 2010, Connan et 
al. 2007). Also, this group of cells has been considered to participate in generating 
strongly anorexigenic effects. Satiety, caused by intracerebroventricular (i.v.) 
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administration of nesfatin-1 is relieved by administration of the CRF2 receptor 
antagonist - astressin2-B (Yosten and Samson 2010). It has also been noted that the 
injection of -MSH to the rat cerebral ventricles increases the expression of NUCB2 
mRNA, a protein precursor of nesfatin-1 in the PVN neurons. This suggests that the cells 
which synthesize this peptide, act through the melanocortin receptors (Maejima et al. 
2009)Although the mechanisms of these actions are still unknown, the veracity of the 
proposed hypothesis is supported by the fact that the change of NUCB2 expression 
levels had not been reported after prior use of SHU9119, a selective antagonist of 
melanocortin MC3 and MC4 receptors (Brailoiu et al. 2007). The melanocortin MC4 
receptor in PVN plays a crucial role in the regulation of eating process, and therefore, 
one may speculate that the nesfatin-1 neurons, displaying coexpression of oxytocin, 
vasopressin, and CRF are the effectors in melanocortin signalization pathway (Kishi et al. 
2003, Yosten and Samson 2009). It has also been reported that upon refeeding c-Fos 
expression in abdominal neurons of parvocellular PVN layer depends on the 
melanocortin signaling (Singru et al. 2007). One probable explanation may be that the 
initiation of feeding, after a period of starvation, affects the POMC neurons, which 
induce c-Fos expression in nesfatin-1 hypothalamic neurons. In addition, neuromedin U 
(NMU) can be regulated by nesfatin-1, because after its i.v. injection, the increase of c-
Fos expression occurs in PVN and SON (Ozaki et al. 2002). It is worth noticing that one of 
the factors that activates nesfatin PVN and NTS neurons is an anorectic intestinal 
hormone cholecystokinin CCK-8S (Noetzel et al. 2009). A potential participation of 
nesfatin-1 in the gut-hypothalamus regulatory axis is supported by recent reports that 
abdominal surgery activates nesfatin-1 hypothalamic neurons (SON and PVN) of the rat 
(Stengel et al. 2010b). In contrast, an intraperitoneal injection of this peptide reduces 
the stomach emptying in rats (Stengel et al. 2009). In turn, an i.v. administration of 






3. Involvement of nesfatin-1 in the regulation of reproductive processes 
 
A multilevel regulatory activity of autonomic centres and neuronal pathways is a 
noteworthy characteristic of many hypothalamic structures. The same groups of 
neurons are simultaneously involved in the performance of many regulatory functions. 
The aforementioned neurons of the hypothalamic nuclei: ARC, PVN, SON and LHA are 
responsible for maintenance of energetic and osmotic homeostasis. They are also 
involved in the central regulation of reproductive processes, including sexual maturation 
and mating behaviour. Expression of nesfatin-1 in these nuclei suggests its contribution 
to these physiological activities. The newest research studies seem to confirm these 
presumptions, and have found that nesfatin-1 expression in the rat hypothalamic nuclei 
increases significantly during the course of sexual maturation, and then achieves its 
peak between the 20-th and 35-th day of life. At that time, a 3-fold increase in the total 
amount of neuropeptide protein in PVN, SON and LHA occurs (Garcia-Galiano et al. 
2010). It should be emphasized that this effect can be greatly disturbed by negative 
energy balance, caused by a short-term starvation or nutritional deficiency. It has also 
been noted that the intracerebroventricular administration of nesfatin-1 induces a 
significant, above 2-fold, increase in the LH concentration in the serum of female rats, 
being fed in a standard way. In contrast, the short-term starvation causes a dramatic 
increase of the gonadotropin responses to nesfatin-1.  A 9-fold increase in the LH level, 
within 15 minutes after an injection has been reported (Garcia-Galiano et al. 2010). 
During puberty, a functional blockage of nesfatin-1 in hypothalamus delays an 
appearance of external sexual signs (e.g.: vaginal opening), causes a decrease of the 
ovarian mass, and a reduction of the LH serum concentration. Thus, some valid 
presumptions exist that nesfatin-1 can also participate in the regulation of gonadotropin 
secretion in adulthood. Despite some preliminary studies, which have not revealed any 
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statistically significant differences in the gonadotropin levels among adult female rats 
exposed to the central action of nesfatin-1 (Garcia-Galiano et al. 2010), some reports 
have appeared, suggesting that the high doses of this neuropeptide can modulate the 
LH and FSH concentrations in male adult rats (Tadross et al. 2010). Although full 
explanation of this problem requires further studies, even at the present stage of 
knowledge, nesfatin-1 can be considered as one of the regulatory factors of the 
hypothalamic-pituitary-axis. Some signaling processes, in which it is involved, make an 
important contribution to the gonadotropin secretion during puberty. It should also be 
underlined that these processes are downregulated by distorted energy homeostasis. 
 
 
4. Neuropsychiatric aspects of nesfatin-1 physiological actions 
 
4.1 Stress responses and depression 
Many of the recent studies suggest that acute restrain stress is one of the factors 
activating nesfatin PVN, SON, NTS and EW neurons (Stengel et al. 2010a, Goebel et al. 
2009) (Fig 3.). Total adrenalectomy leads to an increase of NUCB2 mRNA expression in 
PVN, and i.v. nesfatin-1 injection causes an elevation of the stress hormones: ACTH and 
corticosterone in the serum (Könczöl et al. 2010). Nesfatin-1 seems to contribute to 
generalized signs of stress. Administration of this peptide into lateral ventricles of the 
rat brain causes an elevation of blood pressure (Yosten et Samson. 2009). It has been 
suggested that the  hypertensive  effects of centrally administered nesfatin-1 is also the 
result of stimulation of renal sympathetic nerves, mediated via melanocortin 
hypothalamic pathways (Tanida and Mori 2011). In addition, it has been noted that the 
expression of nesfatin-1 in raphe nuclei, LC and EW neurons, in rats exposed to action of 
different stressors such as wrap restraint stress (Okere et al.  2010, Goebel et al. 2009,), 
abdominal surgery (Stengel et al. 2010b) and lipopolysaccharide administration was 
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increased (Bonnet et al. 2009). Nesfatin-1 activates stress-sensitive serotoninergic 
neurons of raphe nuclei, and noradrenergic LC neurons, which in turn stimulate the CRF 
neurons in PVN, and then activate the HPA axis (Yoshida et al. 2010). It has been known 
that the raphe nuclei and LC are also the key centres of the serotoninergic and 
noradrenergic brain signaling system. Their dysfunctions are closely correlated with 
pathogenesis of depression and anxiety disorders. At the present time, it seems 
probable that nesfatin-1 can play a hypothetical and nonspecific role in some of these 
mechanisms. Some authors suggest that nesfatin-1 induces anxiety or fear reactions 
(Merali et al. 2008, Oh et al. 2006) and perhaps depressive reactions (Chaki and Okubo 
2007), via activation of melanocortin pathways. This results in inhibition of GABA-ergic 
neurons  or alternatively, in hyperpolarization of NPY neurons in the arcuate nucleus 
(Domschke et al. 2010). In patients with major depressive disorder (MDD), a higher 
serum nesfatin-1 level has been revealed, comparing to the one reported in the normal 
population (Ari et al. 2011). In general, these results support bidirectional permeability 
of blood-brain barrier for nesfatin-1. However, at the present moment, these findings 
are still difficult to interpret. This is due to lack of information, indicating which neuronal 
cell populations of the brain are responsible for the increased nesfatin-1 secretion in 
patients with MDD. The underlying mechanism of this phenomenon is still unclear. Also, 
it cannot be excluded that the additional source of circulating nesfatin-1 may be 
secondarily activated by some cells, located outside of the CNS. An intriguing study 
performed recently by Bloem et al. (2011) has shown that nesfatin-1/NUCB2 mRNA 
expression in the human Westphal-Edinger nucleus (EW) was higher in suicidal cases 
among males (all victims did not have previously diagnosed psychiatric or 
neurodegenerative disorders), whereas among females, this content was lower, 
compared to controls. The authors have also found nesfatin-1/NUCB2 and CART 
colocalization in the EW, and they were the first to show sex-related changes in the 
neuropeptides levels in the brain stem of suicide victims versus controls. These findings 
may suggest the existence of nesfatin-CART interplay in the midbrain. However, due to 
lack of other evidence on this topic, they are still difficult to interpret. Undoubtedly, the 
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potential role of nesfatin-1 signaling in the pathogenesis of depressive-like behaviour 
requires further study. 
 
 
4.2. Eating disorders 
Due to some anorexigenic properties of nesfatin-1, it seems justified to conduct further 
research studies analyzing its potential role in pathogenesis of psychogenic eating 
disorders. Recently, it has been noted that plasma nesfatin-1 levels in patients suffering 
from restricting-type anorexia nervosa (AN-R) were significantly lower, compared with 
healthy persons. This may indicate a negative correlation with ghrelin and des-acyl 
ghrelin levels. In contrast, a positive correlation between nesfatin-1 levels and BMI was 
demonstrated (Ogiso et al. 2011). An opposite phenomenon was displayed in healthy 
men, with normal body mass index, in whom the fasting nesfatin-1 concentration 
negatively correlated with their BMI (Tsuchiya et al. 2010). This observation was similar 
to the one reported in rats (Stengel et al. 2009). However, there is still no convincing 
evidence that the low nesfatin-1 level underlies anxiety disorders, often accompanying 
AN-R. On the other hand, it cannot be excluded that during periods of extreme 
starvation, even the decreased nesfatin-1 level may reduce anxiety or fear, and 
stimulate food-intake. Unfortunately, a very limited number of research papers on this 
topic does not allow us to precisely interpret these phenomena. It appears that some 
valuable data, contributing to this discussion, could be provided by brain imaging 







The initial interesting reports regarding correlations between nesfatin-1 levels in body 
fluids and a course of epilepsy were published by Aydin et al. in 2009. It was noted that 
the primary generalized epilepsy (PGE) and secondary generalized seizures (SGE) 
significantly elevated nesfatin-1 levels in the patients’ plasma and saliva. During 
treatment, there was a decrease of this neuropeptide concentration, but nevertheless, 
it did not reach the level which is typical for healthy individuals. The newest studies, 
conducted by the same authors support the previous data. They also indicate that the 
plasma nesfatin-1 level is in the highest range during the 5 minutes after onset of the 
PGE and SGE attack. After that, it decreases significantly, and then, after 48 hours, it 
decreases to approximately 50% of its original level (Aydin et al. 2011). However, the 
exact mechanisms of these changes have not been clearly explained. Some hypotheses 
have been formulated that the elevated nesfatin-1 level can induce some excitotoxic 
effects that may disturb certain activities of cortical and subcortical neuronal circuitries. 
This may result in onset of epileptic symptoms.  
It has also been found that the plasma nesfatin-1 level was significantly elevated in rats 
with epileptic seizures, induced by kainic acid. This suggests that the plasma level of this 
neuropeptide may illustrate a profile of its fluctuation in hypothalamus. (Liu et al. 2011)  
Although this issue certainly requires further study, at the present time, nesfatin-1 can 
be considered as a valuable and promising marker of epileptic episodes, being 







5. Concluding remarks 
Nesfatin-1 is a neuropeptide characterized by a wide spectrum of activity in the CNS. 
There is some evidence to consider nesfatin-1 as a promising factor which can be useful 
for clinical application. It can be potentially helpful in the therapy of metabolic 
disorders, and obesity of various origins. Elevated plasma nesfatin-1 levels in patients 
suffering from primary generalized epileptic seizures, suggests its potential use as a 
biomarker in epilepsy diagnostic work-up (Aydin et al. 2009). Increase in body mass and 
BMI among psychiatric patients taking antipsychotic, antidepressive, and other 
psychotropic medications represents a huge clinical problem. In many of these obese 
patients, a substantial reduction of sensitivity to leptin or some other adipokines may 
occur, in various hypothalamic centres (Haymsfield et al. 1999). It seems that in these 
cases, the use of nesfatin-1 can cause a substantial clinical improvement. Based on 
experimental studies, an intraperitoneal administration of nesfatin-1 has significantly 
reduced food intake in leptin-resistant animals. In addition, nesfatin-1 has been found to 
reduce an elevated body mass of experimental animals. A possible relationship between 
nesfatin-1 action and appetite regulation in patients suffering from chronic kidney 
disesase (CKD) has also been cautiously postulated (Saldanha et al. 2011). 
One possible way of administration of this agent is a subcutaneous injection. However, a 
particularly interesting and beneficial therapeutic view seems to be its intranasal 
administration. It has been effective in some experimental animal models (Shimizu et al. 
2009). Although the results of many experimental studies are encouraging, any possible 
clinical applications of nesfatin-1 still remain in the area of speculation. Further research 
on this topic certainly merits attention. In the mean time, answers to several questions, 
concerning pharmacokinetics, potential adverse drug reactions, tolerability profile and 
interactions with other medications are required. Another potential research direction 
consists of searching for selective nesfatin-1 antagonists that perhaps can contribute to 
opening of a new chapter in therapy of eating disorders such as anorexia nervosa. 
However it should be emphasized that the nesfatin-1 receptor so far remains uncloned. 
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Fig. 1. The primary structure of nesfatin-1 and its prohormone NUCB2. (A) SP, signal 
peptide. Nesfatin-1 interaction with a putative G-coupled receptor leads to opening of 
the calcium channels (L and P/Q) or/and to activating of the adenylate cyclase pathway 
and protein kinase A in the hypothalamic neurons. The neuropeptide may also inhibit 
the NPY/AgRP cells directly, causing their hyperpolarization, through the ATP-dependent 



























Fig 2. Schematic representation of nesfatin-1 neuronanatomical distribution in the rat 
hypothalamus. (A) ARC, arcuate nucleus; DMH, dorsomedial hypothalmus; LHA, lateral 
hypothalamus;  PVN, paraventricular nucleus; SON, supraoptic nucleus; ZI, zona incerta. 
Rat brain coronal sections according to Paxinos G., Watson C.; Rat Brain Atlas (2007); -
2.04 mm (A1) and -2.52mm (A2) from bregma. The highest level of nesfatin-1 
immunoreactivity was detected at the LHA, PVN, SON (red areas) and fainter reaction 
was observed at the ZI, ARC and DMH (blue areas).  Coexpression of nesfatin-1 
immunoreactivity with other hypothalamic peptides (B). The graph shows the mean 
percentage of neurons positive for other transmitters colocalized with nesfatin-1. a-
MSH, Melanocyte stimulating hormone ; CRF, corticotropin releasing factor; CART, 
cocaine-amphetamine regulated transcript; GHRH, growth hormone-releasing hormone; 

















Fig. 3. An outline model of the stimulatory (black arrows) and inhibitory (round-ended 
line) regulation of nesfatin-1 signaling pathways in the rat brain. The picture emphasizes 
the important role of stress factors. DR, dorsal raphe; EW, Westphal-Edinger nucleus; 
LC, locus coeruleus; NTS, nucleus of the solitary tract;  PVN, paraventricular nucleus; 
SON supraoptic nucleus. See text for further details. 
 
 
 
